Literature DB >> 10405115

Hyperresponsiveness to palatable and aversive taste stimuli in genetically obese (bombesin receptor subtype-3-deficient) mice.

K Yamada1, E Wada, J Imaki, H Ohki-Hamazaki, K Wada.   

Abstract

Taste preference in obese mice was examined using genetically obese (bombesin receptor subtype-3: BRS-3 deficient) animals. Preference for either sodium saccharin (0.2%). sodium chloride (0.9%), citric acid (0.1%), or quinine sulfate (0.002%) solution was examined using a two-bottle test situation, and BRS-3 deficient mice not only showed a stronger preference for saccharin solution, but also a stronger aversive response to quinine solution, relative to wild-type littermates. Furthermore, a conditioned taste-aversion test measured the consumption of sodium saccharin (0.2%) and sodium chloride (0.9%) solutions after intraperitoneal injection of LiCl (0.3 M, 1 mg/kg), and BRS-3-deficient mice exhibited stronger aversion to both solutions than did control animals. In situ hybridization demonstrated that the BRS-3 gene is expressed in the parabrachial nucleus, the medial and central nuclei of the amygdala, and the hypothalamic nuclei such as paraventricular nucleus, all of which are known to be involved in taste perception. These results suggest that expression of the BRS-3 gene in these nuclei is important for the modulation of taste preference, as well as the development of obesity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405115     DOI: 10.1016/s0031-9384(99)00032-3

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  13 in total

1.  Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.

Authors:  Marc L Reitman; Victor Dishy; Allison Moreau; William S Denney; Chengcheng Liu; Walter K Kraft; Alex V Mejia; Mark A Matson; S Aubrey Stoch; John A Wagner; Eseng Lai
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

Review 3.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

4.  A selective human bombesin receptor subtype-3 peptide agonist mediates CREB phosphorylation and transactivation.

Authors:  Xiaoqun Qin; Xiangping Qu; David Coy; H Christian Weber
Journal:  J Mol Neurosci       Date:  2011-11-30       Impact factor: 3.444

5.  ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.

Authors:  Terry W Moody; Samuel A Mantey; Paola Moreno; Taichi Nakamura; Enza Lacivita; Marcello Leopoldo; Robert T Jensen
Journal:  Peptides       Date:  2014-12-30       Impact factor: 3.750

6.  Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirect pathways.

Authors:  Naoki Furutani; Mari Hondo; Natsuko Tsujino; Takeshi Sakurai
Journal:  J Mol Neurosci       Date:  2010-05-14       Impact factor: 3.444

7.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

8.  Factors contributing to obesity in bombesin receptor subtype-3-deficient mice.

Authors:  Ellen E Ladenheim; Nahketah L Hamilton; Robert R Behles; Sheng Bi; Lori L Hampton; James F Battey; Timothy H Moran
Journal:  Endocrinology       Date:  2007-11-26       Impact factor: 4.736

Review 9.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

10.  Cre Recombinase Driver Mice Reveal Lineage-Dependent and -Independent Expression of Brs3 in the Mouse Brain.

Authors:  Allison S Mogul; Colleen K Hadley; Haley S Province; Jordan Pauli; Oksana Gavrilova; Cuiying Xiao; Richard D Palmiter; Ramón A Piñol; Marc L Reitman
Journal:  eNeuro       Date:  2021-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.